Journal/ Conference Pub Date Title Author(s) Author Affiliation Copyright Assertion DOI Author categories Textual Evidence Work of Gov't Disclaimer Other Disclaimers Preparers Comments
Clin Cancer Res 2007;13(17) Sep-07 Long-term Evaluation of Three Multiple-Case Waldenstrom Macroglobulinemia Families Mary L. McMaster,1,4 Gyorgy Csako,2 Therese R. Giambarresi,3 LindaVasquez,3 Melissa Berg,1
Stephanie Saddlemire,1
Benjamin Hulley,1
and Margaret A.Tucker1,4		 1 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute,
2 Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland,
3 Westat, Rockville, Maryland
4 Commissioned Corps, U.S. Public Health Service, Department of Health and Human Services,Washington, District of Columbia		 © 2007 American Association for Cancer 10.1158/1078-0432.CCR-07-0299 Employee 1 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute,
2 Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland,
4 Commissioned Corps, U.S. Public Health Service, Department of Health and Human Services,Washington, District of Columbia		 No We thank W. Blattner, G. Shaw, and J.F. Fraumeni, Jr., for their invaluable and far-sighted contributions to family ascertainment and initial evaluation; E. Jaffe, P. Noel, and M. Rick for their expert pathology review; and A. Goldstein, D. Parry, R. Yang, and P. Taylor for their critical review of the manuscript.
Grant support: Intramural Research Program of the NIH (National Cancer Institute and Clinical Center).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 71, Issue 8 Supplement Apr-11 Abstract 5560: All three positional isomers of acetyl salicylic acids are equally potent in inhibiting colon cancer cell growth: Differences in mode of COX inhibition Zong Yuan Gan1, Ravinder Kodela1, Satindra Goswami1, Mitali Chattopadhyay1, Daniel Boring2, James A. Crowell2, and Khosrow Kashfi1 1City Univ. of New York Medical School, New York, NY
2Division of Cancer Prevention, NCI-NIH, Bethesda, MD.		 ©2011 American Association for Cancer Research 10.1158/1538-7445.AM2011-5560 Employee 2Division of Cancer Prevention, NCI-NIH, Bethesda, MD. No N/A
Clin Cancer Res; 21(12) June 15, 2015 Jun-15 FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma Hyon-Zu Lee 1, Virginia E. Kwitkowski 1, Pedro L. Del Valle 1, M. Stacey Ricci 1, Haleh Saber 1, Bahru A. Habtemariam 2, Julie Bullock 2, Erik Bloomquist 3, Yuan Li Shen 3, Xiao-Hong Chen 4, Janice Brown 4, Nitin Mehrotra 2, Sarah Dorff 2, Rosane Charlab 2, Robert C. Kane 1, Edvardas Kaminskas 1, Robert Justice 1, Ann T. Farrell 1, and Richard Pazdur 1 1 Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
2 Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
3 Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
4 Office of New Drug Quality Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.		 This is a U.S. Government work. There are no restrictions on its use.
© 2015 American Association for Cancer Research		 10.1158/1078-0432.CCR-14-3119 Employee 1 Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
2 Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
3 Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
4 Office of New Drug Quality Assessment, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.		 Yes The authors thank Jessica Boehmer for her assistance in coordinating the review of this New Drug Application.
Mol Cancer Res; 12(8) August 2014 Aug-14 Cooperativity of E-cadherin and Smad4 Loss to Promote Diffuse-Type Gastric Adenocarcinoma and Metastasis Jun Won Park1,2, Seok Hoon Jang1, Dong Min Park1, Na Jung Lim1, Chuxia Deng3, Dae Yong Kim2, Jeffrey E. Green4, and Hark Kyun Kim1 1 Biomolecular Function Research Branch, National Cancer Center, Goyang, Gyeonggi;
2 College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea;
3 National Institute of Diabetes and Digestive and Kidney Diseases; and
4 Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland		 © 2014 American Association for Cancer Research. 10.1158/1541-7786.MCR-14-0192-T Employee 3 National Institute of Diabetes and Digestive and Kidney Diseases; and
4 Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, Maryland		 No The study sponsor has no roles in the study design in the collection, analysis, and interpretation of data.
This work was supported by the Proteogenomic Research Program through the National Research Foundation of Korea and the Converging Research Center Program (2013K000429) funded by the Korean Ministry of Education, Science and Technology; by National Cancer Center Grant 1210051; and by the NIH intramural program, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 74, Issue 19 Supplement Oct-14 Abstract 1859: Potential impact on the biology and biomarker utility of ERG-typing in the context of ethnic differences of prostate cancer Albert Dobi1, Yongmei Chen1, Amina Ali1, Denise Young1, Philip Rosen2, James Farrell2, Michael Degon2, Sudhir Srivastava3, Jacob Kagan3, Jocelyn Lee3, Jennifer Cullen1, Gyorgy Petrovics1, David G. McLeod1, Isabell A. Sesterhenn4, and Shiv Srivastava1 1 CPDR, Department of Surgery, USUHS, Rockville, MD;
2 Walter Reed National Military Medical Center, Bethesda, MD;
3 Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD;
4 Joint Pathology Center, Silver Spring, MD.		 ©2014 American Association for Cancer Research. 10.1158/1538-7445.AM2014-1859 Employee 1 CPDR, Department of Surgery, USUHS, Rockville, MD;
2 Walter Reed National Military Medical Center, Bethesda, MD;
3 Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD;		 No N/A
Cancer Epidemiol Biomarkers Prev; 20(6) June 2011 Jun-11 Low Plasma Coenzyme Q10 Levels and Breast Cancer Risk in Chinese Women Robert V. Cooney1, Qi Dai3, Yu-Tang Gao4, Wong-Ho Chow5, Adrian A. Franke2, Xiao-Ou Shu3, Honglan Li4, Butian Ji5, Qiuyin Cai3, Weiwen Chai2, and Wei Zheng3 1 Office of Public Health Studies, John A. Burns School of Medicine;
2 Cancer Research Center, University of Hawaii at Manoa, Honolulu, Hawaii;
3 Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee;
4 Shanghai Cancer Institute, Shanghai, China;
5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland		 ©2011 American Association for Cancer Research. 10.1158/1055-9965.EPI-10-1261 Employee 5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland No This work was supported by NIH Grants CA132149 (RVC), CA106591 (QD), CA90956 (WC), CA71789 (AAF), and CA70867 (WZ). Sample preparations were performed at the Survey and Biospecimen Core, which is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 70, Issue 24 Supplement Dec-10 Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer 1) LN Harris, Z Liu, A Li, E Sprecher, S Sarkar, K Lezon-Geyda, I Krop, EP Winer, and DP. Tuck 1) Yale School of Medicine, New Haven, CT; Dana-Farber Cancer Institute, Boston, MA N/A 10.1158/0008-5472.SABCS10-PD07-08 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 70, Issue 13 Jul-10 A Need for Basic Research on Fluid-Based Early Detection Biomarkers Katherine J. Martin1, Marcia V. Fournier1, G. Prem Veer Reddy2, and Arthur B. Pardee3 1 Bioarray Therapeutics Inc., Belmont, Massachusetts;
2 Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan;
3 Dana-Farber Cancer Institute, Boston, Massachusetts		 N/A 10.1158/0008-5472.CAN-10-0987 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 71, Issue 10 May-11 ΔNp63 Versatilely Regulates a Broad NF-κB Gene Program and Promotes Squamous Epithelial Proliferation, Migration, and Inflammation Xinping Yang1, Hai Lu1, Bin Yan1, Rose-Anne Romano2, Yansong Bian1, Jay Friedman1, Praveen Duggal1, Clint Allen1,3, Ryan Chuang1, Reza Ehsanian1,4,5, Han Si1, Satrajit Sinha2, Carter Van Waes1, and Zhong Chen1 1 Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland;
2 Department of Biochemistry, State University of New York at Buffalo, Center for Excellence in Bioinformatics and Life Sciences, Buffalo, New York;
3 Clinical Research Training Program supported jointly by NIH and Pfizer Inc.;
4 Howard Hughes Medical Institute–NIH Research Scholars Program;
5 Graduate Partnership Program of NIH and Oxford University, United Kingdom		 ©2011 American Association for Cancer Research. 10.1158/0008-5472.CAN-10-3445 Employee 1 Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland; No This project is supported by NIDCD Intramural projects ZIA-DC-00016, ZIA-DC-00073, and ZIA-DC-00074 and a grant from NIH R01AR049238 (S. Sinha).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors thank Drs. Liesl Nottingham, Mathew Brown, Ning T. Yeh (NIDCD/NIH), and Chris Silvin (NHGRI/NIH) for their technical assistance; Drs. Paul Meltzer (NCI/NIH), Maranke Koster (University of Colorado, Denver), and Yong-Jun Liu (The University of Texas MD Anderson Cancer Center) for critique of the manuscript; Drs. Kathryn E. King and Wendy C. Weinberg (FDA) for providing lysates of cells overexpressing ΔNp63 and their scientific recommendations for the project; and Drs. James W. Rocco and Leif W. Ellisen for providing ΔNp63 and TAp63 expression vectors. We also express appreciation to Ms. Cindy Clark (NIH library) for editing of the manuscript.
Mol Cancer Ther 2006;5(10). Oct-06 Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases Chih-hung Lee1, Takashi Kakinuma1, Julia Wang1, Hong Zhang1, Douglas C. Palmer2, Nicholas P. Restifo2 and Sam T. Hwang1 1Dermatology and 2Surgery Branches, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland © 2006 American Association for Cancer Research. 10.1158/1535-7163.MCT-06-0310 Employee 1Dermatology and 2Surgery Branches, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland No We thank Dr. Mark C. Udey (National Cancer Institute) and members of the Hwang laboratory for many helpful suggestions.
Grant support: Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and a Howard Hughes Medical Student Fellowship (J. Wang).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clin Cancer Res 2007;13(4) Feb-07 Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer Lyndsay N. Harris1, Fanglei You1, Stuart J. Schnitt2, Agnes Witkiewicz2, Xin Lu1,3, Dennis Sgroi4, Paula D. Ryan4, Steven E. Come2, Harold J. Burstein1,5, Beth-Ann Lesnikoski5, Madhavi Kamma1,5, Paula N. Friedman6, Rebecca Gelman1,3, J. Dirk Iglehart1,5 and Eric P. Winer1,5 1Dana-Farber Cancer Institute;
2Beth Israel Deaconess Medical Center;
3Biostatistics Department, Harvard School of Public Health;
4Massachusetts General Hospital;
5Brigham and Women's Hospital, Boston, Massachusetts
6Abbott Molecular, Des Plaines, Illinois		 N/A 10.1158/1078-0432.CCR-06-1304 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res 2006;12(3) Feb-06 Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling Ben Davidson1,4, Virginia Espina2, Seth M. Steinberg3, Vivi Ann Flørenes4, Lance A. Liotta2, Gunnar B. Kristensen5, Claes G. Tropé5, Aasmund Berner4 and Elise C. Kohn1,2 1Molecular Signaling Section, 2National Cancer Institute-Food and Drug Administration Clinical Proteomics Group, Laboratory of Pathology,
3Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda Maryland;
Departments of 4 Pathology and 5 Gynecologic Oncology, The Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway		 © 2006 American Association for Cancer 10.1158/1078-0432.CCR-05-2516 Employee 1Molecular Signaling Section, 2National Cancer Institute-Food and Drug Administration Clinical Proteomics Group, Laboratory of Pathology,
3Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda Maryland; 		No The authors thank M. Winters and S. Cowherd (Clinical Proteomics Group, National Cancer Institute, Bethesda, Maryland), and M. Skrede (Department of Pathology, Norwegian Radium Hospital, University of Oslo, Montebello, Oslo, Norway) for their technical assistance.
Grant support: Norwegian Cancer Society. Materials in this manuscript could be the subject of U.S. Government-owned patents or patent applications.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 75, Issue 24 Dec-15 SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex Yongmei Feng1, Anthony B. Pinkerton1, Laura Hulea2,3, Tongwu Zhang4, Michael A. Davies5, Stefan Grotegut1, Yann Cheli1, Hongwei Yin6, Eric Lau1, Hyungsoo Kim1, Surya K. De1, Elisa Barile1, Maurizio Pellecchia1, Marcus Bosenberg7, Jian-Liang Li1, Brian James1, Christian A. Hassig1, Kevin M. Brown4, Ivan Topisirovic2,3, and Ze'ev A. Ronai1 1 Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
2 Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montréal, Canada.
3 Department of Oncology, McGill University, Montréal, Canada.
4 Division of Cancer Epidemiology and Genetics, Laboratory of Translational Genomics, NCI, Bethesda, Maryland.
5 Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas.
6 Cancer and Cell Biology Division, The Translational Genomics Research Institute (TGen), Phoenix, Arizona.
7 Departments of Dermatology and Pathology, Yale University, School of Medicine, New Haven, Connecticut.		 © 2015 American Association for Cancer Research. 10.1158/0008-5472.CAN-15-0885 Employee 4 Division of Cancer Epidemiology and Genetics, Laboratory of Translational Genomics, NCI, Bethesda, Maryland. No This work was supported by the Melanoma Research Alliance. Core Services were supported by NCI Cancer Center grant P30 CA30199 (Z.A. Ronai) and CA016672 (M.A. Davies). This work was also supported by the Assistant Secretary of Defense for Health Affairs through the Peer-Reviewed Cancer Program under Award No. W81XWH-14-1-0127 (Z.A. Ronai), CIHR (MOP-115-195), CRS (01713), and CIHR new investigator salary award (IT), and by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics; National Cancer Institute (T. Zhang and K.M. Brown)
The authors thank members of the Genomic, Proteomic, and Animal Cores at SBP and Ronai lab members for discussions, as well as the Cancer Genomics Research Laboratory (CGR) at the NCI. The authors also thank Dr. Jerry Pelletier for providing luciferase constructs for in vitro translation assays. This article is dedicated in fond memory of Greg Roth, Ph.D., their colleague at Sanford Burnham Prebys Lake Nona, for his wisdom, compassion, integrity, his love of the sciences, and his contributions to the development of clinically meaningful projects.
Clin Cancer Res Volume 20, Issue 19 Oct-14 Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303 Ann Marie Egloff1, Ju-Whei Lee2, Corey J. Langer3, Harry Quon4, Alec Vaezi1, Jennifer R. Grandis1, Raja R. Seethala1, Lin Wang1, Dong M. Shin5, Athanassios Argiris1, Donghua Yang3, Ranee Mehra3, John Andrew Ridge3, Urjeet A. Patel6, Barbara A. Burtness3, and Arlene A. Forastiere7 1 University of Pittsburgh, Pittsburgh, Pennsylvania.
2 Dana-Farber Cancer Institute, Boston, Massachusetts.
3 Fox Chase Cancer Center, Philadelphia, Pennsylvania.
4 University of Pennsylvania, Philadelphia, Pennsylvania.
5 Emory University, Atlanta, Georgia.
6 Northwestern University, Chicago, Illinois.
7 Johns Hopkins University School of Medicine and Sydney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.		 N/A 10.1158/1078-0432.CCR-14-0051 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 77, Issue 6 Mar-17 Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation Ye Cui1, Wendy K. Steagall2, Anthony M. Lamattina1, Gustavo Pacheco-Rodriguez2, Mario Stylianou3, Pranav Kidambi1, Benjamin Stump1, Fernanda Golzarri1, Ivan O. Rosas1, Carmen Priolo1, Elizabeth P. Henske1, Joel Moss2, and Souheil El-Chemaly1 1 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2 Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
3 Office of Biostatistics Research, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.		 ©2017 American Association for Cancer Research. 10.1158/0008-5472.CAN-16-2755 Employee 2 Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
3 Office of Biostatistics Research, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.		 No This work was supported in part by the Department of Defense (TS130031 to S. El-Chemaly), NIH grant R01 HL130275 to S. El-Chemaly, the Anne Levine LAM Research Fund to S. El-Chemaly, BRI microgrant (Y. Cui), The Lucy J. Engles TSC/LAM Research Program (EP. Henske) and the Division of Intramural Research NIH/NHLBI.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors are grateful to lymphangioleiomyomatosis patients and their families for their participation in this research. We would also like to thank Leigh Samsel, Venina Dominical, and J. Philip McCoy of the Flow Cytometry Core at NIH/NHLBI for their excellent technical assistance.
Cancer Research Volume 75, Issue 15 Supplement Aug-15 Abstract 4344: Olfactomedin 4 plays a tumor-suppressor role and is a novel candidate biomarker in the prostate cancer progression and independent of PSA 1) Hongzhen Li, Ye Chen, Wenli Liu, Jianqiong Zhu, Chin Kay, Xujing Wang, and Griffin P. Rodgers 1) NIH-NHLBI, Bethesda, MD. ©2015 American Association for Cancer Research. 10.1158/1538-7445.AM2015-4344 Employee 1) NIH-NHLBI, Bethesda, MD. No N/A
Cancer Research Volume 72, Issue 24 Supplement Dec-12 Abstract P1-05-23: Blockade of mTORC1 decreases CXCR4-mediated migration and metastasis 1) Pilla P Dillenburg, VT Patel, R Dorsam, A Masedunskas, P Amornphimoltham, R Weigert, A Molinolo, and JS Gutkind 1) NIH, Bethesda, MD © 2012 10.1158/0008-5472.SABCS12-P1-05-23 Employee 1) NIH, Bethesda, MD No N/A
Clin Cancer Res Volume 19, Issue 22 Nov-13 Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia Mauricio Burotto1, Maryalice Stetler-Stevenson2, Evgeny Arons1, Hong Zhou1, Wyndham Wilson3, and Robert J. Kreitman1 Laboratories of 1Molecular Biology and 2Pathology, and 3Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland ©2013 American Association for Cancer Research. 10.1158/1078-0432.CCR-13-1848 Employee Laboratories of 1Molecular Biology and 2Pathology, and 3Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland No R.J. Kreitman's laboratory receives research support from Genentech, and the rituximab and bendamustine for this trial was supplied to the NIH from Genentech and Teva (formally Cephalon), respectively. E. Arons also receives research support from Genentech. No potential conflicts of interest were disclosed by the other authors.
This work was supported by the intramural research program, NCI, NIH, and also in part by the Hairy Cell Leukemia Research Foundation.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 75, Issue 15 Supplement Aug-15 Abstract CT222: Ferumoxytol enhanced MRI for lymph node staging in genitourinary cancers Anna M. Brown1, Sandeep Sankineni1, Marcelino Bernardo1, Dagane Daar1, Juanita Weaver1, Yolanda McKinney1, Anna Couvillon2, James L. Gulley3, Bradford J. Wood4, Peter A. Pinto5, William L. Dahut3, Ravi Amrit Madan3, Peter L. Choyke1, and Baris Turkbey1 1 Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD;
2 Genitourinary Malignancies Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD;
3 National Cancer Institute at the National Institutes of Health, Bethesda, MD;
4 Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD;
5 Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD.		 ©2015 American Association for Cancer Research. 10.1158/1538-7445.AM2015-CT222 Employee 1 Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD;
2 Genitourinary Malignancies Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD;
3 National Cancer Institute at the National Institutes of Health, Bethesda, MD;
4 Center for Interventional Oncology, National Cancer Institute, NIH, Bethesda, MD;
5 Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD.		 No N/A
Cancer Research Volume 73, Issue 8 Supplement Apr-13 Abstract LB-297: Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Kyrre E. Emblem1, Kim Mouridsen2, Atle Bjornerud3, Christian T. Farrar1, Dominique Jennings1, Ronald J.H Borra1, Patrick Y. Wen4, Percy Ivy5, Tracy T. Batchelor6, Bruce R. Rosen1, Rakesh K. Jain7, and A. Gregory Sorensen8 1 Department of Radiology and Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA;
2 Center of Functionally Integrative Neuroscience and MINDLab, University of Aarhus, Aarhus, Denmark;
3 The Intervention Centre, Oslo University Hospital, Oslo, Norway;
4 Center For Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA;
5 Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD;
6 Department of Neurology, Massachusetts General Hospital, Boston, MA;
7 Edwin L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA;
8 Siemens Healthcare Health Services, Malvern, PA.		 ©2013 American Association for Cancer Research 10.1158/1538-7445.AM2013-LB-297 Employee 5 Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD; No N/A
Clin Cancer Res Volume 19, Issue 3 Feb-13 Vandetanib for the Treatment of Medullary Thyroid Cancer 1) Nicole G. Chau and Robert I. Haddad 1) Medical Oncology, Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts N/A 10.1158/1078-0432.CCR-12-2353 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res Volume 16, Issue 9 May-10 Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors Quincy Chu1, Alain Mita1, Bahram Forouzesh1, Anthony W. Tolcher1, Gary Schwartz2, Antonio Nieto3, Arturo Soto-Matos3, Vicente Alfaro3, Claudia Lebedinsky3, and Eric K. Rowinsky1 1 Institute for Drug Development, Cancer Therapy and Research Center
2 Brooke Army Medical Center, San Antonio, Texas;
3 PharmaMar Clinical R&D, Colmenar Viejo, Madrid, Spain		 ©2010 American Association for Cancer Research. 10.1158/1078-0432.CCR-10-0062 Employee 2 Brooke Army Medical Center, San Antonio, Texas; No The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 71, Issue 8 Supplement Apr-11 Abstract 3812: Retrospective analysis of Claudin-16 (CLDN16) overexpression in ovarian cancer (OVCA): Evaluation of a biomarker candidate and a novel potential therapeutic target Marcela F. Paes1, Murilo F. Cerri1, Renata D. Daltoé1, Lucas CR Dias1, Alice L. Herlinger1, Klesia P. Madeira1, Débora Silva1, Carlos E. Bacchi2, Ivison X. Duarte2, Patrice J. Morin3, Ian V. Silva1, and Leticia B. Rangel1 1 Federal University of Espirito Santo, Vitória, ES, Brazil
2 Consultoria em Patologia, Botucatu, SP, Brazil
3 National Institute os Health, Vitória, ES, MD.		 N/A 10.1158/1538-7445.AM2011-3812 False Positive 3 National Institute os Health, Vitória, ES, MD. No N/A
Cancer Research Volume 71, Issue 16 Aug-11 YB-1 Bridges Neural Stem Cells and Brain Tumor–Initiating Cells via Its Roles in Differentiation and Cell Growth Abbas Fotovati1, Samah Abu-Ali1, Pei-Shan Wang1, Loic P. Deleyrolle2, Cathy Lee1, Joanna Triscott1, James Y. Chen1, Sonia Franciosi1, Yasuhiro Nakamura3, Yasuo Sugita4, Takeshi Uchiumi5, Michihiko Kuwano5, Blair R. Leavitt1, Sheila K. Singh6, Alexa Jury7, Chris Jones7, Hiroaki Wakimoto8, Brent A. Reynolds2, Catherine J. Pallen1, and Sandra E. Dunn1 1 University of British Columbia, Vancouver, British Columbia, Canada;
2 University of Florida, Gainesville, Florida;
3 St. Mary's Hospital and
4 Kurume University, Kurume;
5 Kyushu University, Fukuoka, Japan;
6 McMaster University, Hamilton, Ontario, Canada;
7 The Institute of Cancer Research, Royal Marsden Hospital, Surrey, England;
8 Massachusetts General Hospital, Boston, 		N/A 10.1158/0008-5472.CAN-10-2805 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res Volume 15, Issue 20 Oct-09 Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer Corey Speers1, Anna Tsimelzon2, Krystal Sexton2, Ashley M. Herrick1, Carolina Gutierrez2, Aedin Culhane4, John Quackenbush4, Susan Hilsenbeck2, Jenny Chang2,3 and Powel Brown2,3 1 Department of Molecular and Cellular Biology,
2 Lester and Sue Smith Breast Center, and
3 Department of Medicine, Baylor College of Medicine, Houston, Texas;
4 Department of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts		 N/A 10.1158/1078-0432.CCR-09-1107 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res Volume 10, Issue 5 Mar-04 Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells Dao M. Nguyen 1 , William D. Schrump 1 , G. Aaron Chen 1 , Wilson Tsai 1 , Phuongmai Nguyen 2 , Jane B. Trepel 2 , and David S. Schrump 1 Thoracic Oncology Section, 1 Surgery Branch, and 2Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland © 2004 American Association for Cancer 10.1158/1078-0432.CCR-0901-3 Employee Thoracic Oncology Section, 1 Surgery Branch, and 2Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland No The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clin Cancer Res Volume 19, Issue 9 May-13 Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study Jong-Lyel Roh1,3, Xin Victoria Wang4,5, Judith Manola4, David Sidransky1, Arlene A. Forastiere2, and Wayne M. Koch1 Departments of 1 Otolaryngology-Head and Neck Surgery and 2 Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland;
3 Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;
4 Dana-Farber Cancer Institute and 5Harvard School of Public Health, Boston, Massachusetts		 N/A 10.1158/1078-0432.CCR-12-3047 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Prev Res Volume 5, Issue 2 Feb-12 N-nitroso-tris-chloroethylurea Induces Premalignant Squamous Dysplasia in Mice Tyler M. Hudish1, Laura I. Opincariu1, Anthony B. Mozer1, Micah S. Johnson1, Timothy G. Cleaver2, Stephen P. Malkoski2, Daniel T. Merrick1, and Robert L. Keith1,2 1 Denver Veterans Affairs Medical Center, Department of Medicine, Denver;
2 Department of Medicine, University of Colorado Denver, Aurora, Colorado		 ©2011 American Association for Cancer Research. 10.1158/1940-6207.CAPR-11-0257 Employee 1 Denver Veterans Affairs Medical Center, Department of Medicine, Denver; No This work was supported by Department of Veterans Affairs Merit Review Program (R.L. Keith) and NCI Grant K08-CA131483 (S.P. Malkoski).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 74, Issue 3 Feb-14 Targeting Akt3 Signaling in Triple-Negative Breast Cancer Y. Rebecca Chin1, Taku Yoshida2,3, Andriy Marusyk2,3, Andrew H. Beck1, Kornelia Polyak2,3,4, and Alex Toker1 1 Department of Pathology, Beth Israel Deaconess Medical Center;
2 Department of Medicine, Harvard Medical School;
3 Department of Medical Oncology, Dana-Farber Cancer Institute;
4 Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts		 N/A 10.1158/0008-5472.CAN-13-2175 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res Volume 13, Issue 8 Apr-07 Phase II Cancer Trials: Out of Control? Bruce Chabner Massachusetts General Hospital, MGH Cancer Center, Boston, Massachusetts N/A 10.1158/1078-0432.CCR-07-0163 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 72, Issue 23 Dec-12 Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4 Ratika Srivastava1, Degui Geng1, Yingjia Liu1, Liqin Zheng3, Zhaoyang Li1, Mary Ann Joseph1, Colleen McKenna1, Navneeta Bansal1, Augusto Ochoa3, and Eduardo Davila1,2 1 Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland;
2 Department of Otorhinolaryngology, Head and Neck Surgery, Baltimore, Maryland;
3 Stanley S. Scott Cancer Center, Louisiana State University, New Orleans, Louisiana		 ©2012 American Association for Cancer Research. 10.1158/0008-5472.CAN-12-0337 Employee 1 Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland; No National Cancer Institute 1R01CA140917-01, NIH Center for Biomedical Research Center Excellence grants 1P20 RR021970, and University of Maryland, Marlene and Stewart Greenebaum Cancer Center.
Cancer Research Volume 75, Issue 15 Aug-15 Abstract 2595: Efficacy of cetuximab and mutant selective EGFR inhibitor WZ4002 in EGFR T790M and non-T790M models of erlotinib resistant non-small cell lung cancer 1) Erin M. Tricker, Chunxiao Xu, Kwok-Kin Wong, and Pasi A. Janne 1) Dana-Farber Cancer Institute, Boston, MA. N/A 10.1158/1538-7445.AM2015-2595 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Epidemiol Biomarkers Prev; 26(3) Mar-17 Early Life Residence, Fish Consumption, and Risk of Breast Cance Alfheidur Haraldsdottir1,2, Laufey Steingrimsdottir1,3, Unnur A. Valdimarsdottir2,4,5, Thor Aspelund2,6, Laufey Tryggvadottir7,8, Tamara B. Harris9, Lenore J. Launer9, Lorelei A. Mucci4,10, Edward L. Giovannucci4,10,11, Hans-Olov Adami4,5, Vilmundur Gudnason6,8, and Johanna E. Torfadottir2,3 1 Faculty of Food Science and Human Nutrition, University of Iceland, Reykjavik, Iceland.
2 Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
3 Unit for Nutrition Research, University of Iceland and Landspitali National University Hospital Reykjavik, Reykjavik, Iceland.
4 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
5 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
6 The Icelandic Heart Association, Kopavogur, Iceland.
7 The Icelandic Cancer Registry, Reykjavik, Iceland.
8 Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
9 Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland.
10 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
11 Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.		 ©2016 American Association for Cancer Research. 10.1158/1055-9965.EPI-16-0473-T Employee 9 Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland. No The AGES-Reykjavik Study was funded by NIH contract N01-AG-12100, the Intramural Research Program of the National Institute on Aging, the Icelandic Heart Association, and the Icelandic Parliament. This work was also supported by the Icelandic Centre for Research, RANNIS grant number: 152495051, http://en.rannis.is/ (to A. Haraldsdottir), and the Public Health Fund of the Icelandic Directorate of Health (to A. Haraldsdottir).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We would like to thank Professor Meir Stampfer at the Department of Epidemiology, Harvard T.H Chan School of Public Health in Boston, for his valuable input to the study design, as well as the pathologists at the Pathology Department at Landpitali National University Hospital, Reykjavik, Iceland
Cancer Epidemiol Biomarkers Prev Volume 14, Issue 2 Feb-05 Exploratory Study of Ovarian Intraepithelial Neoplasia Molly A. Brewer1, James Ranger-Moore2, Amy Baruche3, David S. Alberts4, Mark Greene5, Deborah Thompson6, Yun Liu7, John Davis3 and Peter H. Bartels6 1 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology,
2 Division of Epidemiology and Biostatistics, 3Departments of Pathology, 4Medicine, Pharmacology, and Public Health, 5National Cancer Institute,
6 Optical Sciences Center, 7Arizona Cancer Center, University of Arizona, Tucson, Arizona		 Copyright © 2005 American Association for Cancer Research. 10.1158/1055-9965.EPI-04-0212 Employee 2 Division of Epidemiology and Biostatistics, 3Departments of Pathology, 4Medicine, Pharmacology, and Public Health, 5National Cancer Institute, No Grant support: NIH National Cancer Institute grant CA 53877-13 (P.H. Bartels).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute.
Cancer Research Volume 72, Issue 8 Supplement Apr-12 Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine Diane F. Hale1, Timothy J. Vreeland1, Raetasha S. Dabney1, G Travis Clifton1, Alan K. Sears1, Efi Pappou2, Eleftheria Anastasopoulou2, Alexandros Ardavanis2, Sathibalan Ponniah3, Michael Papamichail2, Sonia Perez2, Nathan Shumway1, George E. Peoples1, and Elizabeth Mittendorf4 1 Brooke Army Medical Center, Ft. Sam Houston, TX
2 St. Savas Cancer Hospital, Athens, Greece, Athens, Greece
3 Cancer Vaccine Development Lab, U.S. Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD
4 University of Texas MD Anderson Cancer Center, Houston, TX		 ©2012 American Association for Cancer Research 10.1158/1538-7445.AM2012-LB-218 Employee 1 Brooke Army Medical Center, Ft. Sam Houston, TX
3 Cancer Vaccine Development Lab, U.S. Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD		 No N/A
Molecular Cancer Research Volume 12, Issue 12 Supplement Dec-14 Abstract IA02: Developing therapies for Ras-driven cancers Karen Cichowski Brigham and Women's Hospital, Harvard Medical School, Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, MA. N/A 10.1158/1557-3125.RASONC14-IA02 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 75, Issue 15 Supplement Aug-15 Abstract 487: Whole genome screen to identify genes targeting MYCN-driven embryonal tumors Carol J. Thiele1, Zhihui Liu1, Veronica Veschi1, Eugene Buehler2, and Scott Martin2 1 National Cancer Institute, Bethesda, MD;
2 National Center For Advancing Translational Sciences, Bethesda, MD.		 ©2015 American Association for Cancer Research. 10.1158/1538-7445.AM2015-487 Employee 1 National Cancer Institute, Bethesda, MD;
2 National Center For Advancing Translational Sciences, Bethesda, MD.		 No N/A
Clin Cancer Res Volume 15, Issue 19 Oct-09 Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma Antoni Ribas1,2,3, Begoña Comin-Anduix2, Bartosz Chmielowski1, Jason Jalil2, Pilar de la Rocha2, Tara A. McCannel4, Maria Teresa Ochoa5, Elizabeth Seja1, Arturo Villanueva1, Denise K. Oseguera1, Bradley R. Straatsma4, Alistair J. Cochran2,3,6, John A. Glaspy1,3, Liu Hui7, Francesco M. Marincola7, Ena Wang7, James S. Economou2,3 and Jesus Gomez-Navarro8 1 Department of Medicine, Division of Hematology/Oncology, 2 Department of Surgery, Division of Surgical Oncology, 3 Jonsson Comprehensive Cancer Center,
4 Department of Ophthalmology and the Jules Stein Eye Institute,
5 Department of Medicine, Division of Dermatology, and 6 Department of Pathology and Laboratory Medicine, University of California at Los Angeles, Los Angeles, California;
7 Infectious Disease and Immunogenetics Section and Center for Human Immunology, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland;
8 Pfizer Global Research and Development, New London, Connecticut		 © 2009 American Association for Cancer Research. 10.1158/1078-0432.CCR-09-1254 Employee 7 Infectious Disease and Immunogenetics Section and Center for Human Immunology, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland; No Grant support: The clinical trial was conducted under a research grant from Pfizer, Inc. This work was additionally supported by the Melanoma Research Foundation, the Harry J. Lloyd Charitable Trust, P50 CA086306, U54 CA119347, and RN2-00902-1 New Faculty Award 2 from the California Institute for Regenerative Medicine (A. Ribas). The University of California at Los Angeles General Clinical Research Center is supported by USPHS grant M01-RR-0865. The University of California at Los Angeles Flow Cytometry Core Facility is supported by the NIH awards CA-16042 and AI-28697.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clin Cancer Research Volume 14, Issue 7 Apr-08 Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer Taro Okazaki1, Li Jiao3, Ping Chang1, Douglas B. Evans2, James L. Abbruzzese1 and Donghui Li1 Departments of 1 Gastrointestinal Medical Oncology and 2 Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
3 Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland		 © 2008 American Association for Cancer Research 10.1158/1078-0432.CCR-07-1520 Employee 3 Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland No Grant support: NIH RO1 grant CA098380 (D. Li), Specialized Programs of Research Excellence P20 grant CA101936 (J.L. Abbruzzese), NIH Cancer Center Core grant CA16672, and Lockton Research Funds research grant (D. Li).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clin Cancer Research Volume 20, Issue 10 May-14 ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy Fan Lin1, Mark C. de Gooijer1,6, Eloy Moreno Roig1, Levi C.M. Buil1, Susan M. Christner5, Jan H. Beumer4,5, Thomas Würdinger6,7, Jos H. Beijnen2,3, and Olaf van Tellingen1 1 General Clinical Lab/Mouse Cancer Clinic, The Netherlands Cancer Institute;
2 Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam;
3 Division of Drug Toxicology, Faculty of Pharmacy; Utrecht University, Utrecht;
4 Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute;
5 Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania;
6 Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands;
7 Molecular Neurogenetics Unit, Departments of Neurology and Radiology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, Massachusetts		 N/A 10.1158/1078-0432.CCR-14-0084 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Molecular Cancer Therapeutics Volume 8, Issue 6 Jun-09 Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer 1) Milos Dokmanovic, Dianne S. Hirsch, Yi Shen and Wen Jin Wu 1) Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland © 2009 American Association for Cancer Research. 10.1158/1535-7163.MCT-09-0140 Employee 1) Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland No The information presented in this article reflects the views of the authors and does not necessarily represent the policy of the U.S. Food and Drug Administration.
We thank Dr. Francisco J. Esteva for providing parental SKBR3 cells and trastuzumab-resistant SKBR3 cells (Clone 3 cells) and Drs. David Frucht, Sarah Kennett, Wendy Weinberg, and Kathleen Clouse for the critical review of this manuscript.
Grant support: U.S. Food and Drug Administration Critical Path Finding for FY2008 and Interagency Oncology Task Force Joint Fellowship Program sponsored by the U.S. Food and Drug Administration and the National Cancer Institute, NIH.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clin Cancer Res Volume 17, Issue 15 Aug-11 Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition Mary Ellen Urick1, Eun Joo Chung1, William P. Shield III1, Naamit Gerber1, Ayla White1, Anastasia Sowers2, Angela Thetford2, Kevin Camphausen1, James Mitchell2, and Deborah E. Citrin1 1Radiation Oncology Branch and 2Radiation Biology Branch, National Institutes of Health, Bethesda, Maryland ©2011 American Association for Cancer Research. 10.1158/1078-0432.CCR-11-0358 Employee 1Radiation Oncology Branch and 2Radiation Biology Branch, National Institutes of Health, Bethesda, Maryland No This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 75, Issue 13 Jul-15 NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation Takeshi Namiki1,2,3, Tomonori Yaguchi2, Kenta Nakamura2,4, Julio C. Valencia1, Sergio G. Coelho1, Lanlan Yin1, Masakazu Kawaguchi1, Wilfred D. Vieira1, Yasuhiko Kaneko5, Atsushi Tanemura6, Ichiro Katayama6, Hiroo Yokozeki3, Yutaka Kawakami2, and Vincent J. Hearing1 1 Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
2 Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
3 Department of Dermatology, Tokyo Medical and Dental University Graduate School and Faculty of Medicine, Bunkyo-ku, Tokyo, Japan.
4 Department of Dermatology, Shinshu University School of Medicine, Matsumoto-shi, Nagano, Japan.
5 Research Institute for Clinical Oncology, Saitama Cancer Center, Kitaadachi, Saitama, Japan.
6 Department of Dermatology, Osaka University Graduate School of Medicine, Suita-shi, Osaka, Japan.		 ©2015 American Association for Cancer Research. 10.1158/0008-5472.CAN-13-3209 Employee 1 Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. No This work was supported in part by the Intramural Research Program (ZIA BC 010785) of the National Cancer Institute at NIH and Grants-in-Aid for Scientific Research (26221005) from the Japan Society for Promotion of Science.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors thank Drs. Murata H and Okuyama R (Shinshu University) for providing the SM2-1 melanoma cell.
Cancer Research Volume 72, Issue 24 Supplement Dec-12 Abstract P2-10-15: Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study 1) DC Sgroi, I Sestak, Y Zhang, MG Erlander, CA Schnabel, PE Goss, J Cuzick, and M Dowsett 1) Massachusetts General Hospital and Harvard Medical School, Boston, MA; Queen Mary University, London, United Kingdom; bioTheranostics Inc, San Diego, CA; Royal Marsden Hospital, London, United Kingdom N/A 10.1158/0008-5472.SABCS12-P2-10-15 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Clin Cancer Res Volume 11, Issue 8 Apr-05 Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Gary J. Kelloff1, John M. Hoffman1, Bruce Johnson2, Howard I. Scher3, Barry A. Siegel4, Edward Y. Cheng5, Bruce D. Cheson6, Joyce O'Shaughnessy7, Kathryn Z. Guyton8, David A. Mankoff9, Lalitha Shankar1, Steven M. Larson3, Caroline C. Sigman8, Richard L. Schilsky10 and Daniel C. Sullivan1 1 Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland;
2 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts;
3 Memorial Sloan-Kettering Cancer Center, New York, New York;
4 Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri;
5 Department of Orthopaedic Surgery, University of Minnesota and Orthopaedic Surgery Service, Fairview University Medical Center, Minneapolis, Minnesota;
6 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia;
7 Baylor Charles A. Sammons Cancer Center, Dallas, Texas;
8 CCS Associates, Mountain View, California;
9 Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington;
10 Section of Hematology/Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois		 © 2005 American Association for Cancer Research. 10.1158/1078-0432.CCR-04-2626 Employee 1 Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; No The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 71, Issue 24 Supplement Dec-11 P2-01-12: Determining the Molecular Signature That Drives Breast Cancer-Induced Brain Metastasis in a Mouse Xenograft Model. KD Mukhopadhyay1, AG Elkahloun1, K Yoon1, JE Cornell1, L Yu1, Z Liu1, and L-Z Sun1 1 UT Health Science Center, San Antonio, TX; National Human Genome Research Institute- NIH, Bethesda, MD © 2011 10.1158/0008-5472.SABCS11-P2-01-12 Unsure 1 UT Health Science Center, San Antonio, TX; National Human Genome Research Institute- NIH, Bethesda, MD No N/A
Clin Cancer Res Volume 16, Issue 2 Jan-10 MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer Maria Teresa Landi1, Yingdong Zhao2, Melissa Rotunno1, Jill Koshiol1, Hui Liu4, Andrew W. Bergen5, Maurizia Rubagotti6, Alisa M. Goldstein1, Ilona Linnoila3, Francesco M. Marincola4, Margaret A. Tucker1, Pier Alberto Bertazzi6, Angela C. Pesatori6, Neil E. Caporaso1, Lisa M. McShane2 and Ena Wang4 Divisions of 1 Cancer Epidemiology and Genetics and 2 Cancer Treatment and Diagnosis, 3 Center for Cancer Research, National Cancer Institute, NIH, Department of Health and Human Services and 4 Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and Center for Human Immunology, NIH, Department of Health and Human Services, Bethesda, Maryland;
5 Center for Health Sciences, SRI International, Menlo Park, California;
6 EPOCA, Epidemiology Research Center, University of Milan, and Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy		 ©2010 American Association for Cancer Research. 10.1158/1078-0432.CCR-09-1736 Employee Divisions of 1 Cancer Epidemiology and Genetics and 2 Cancer Treatment and Diagnosis, 3 Center for Cancer Research, National Cancer Institute, NIH, Department of Health and Human Services and 4 Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and Center for Human Immunology, NIH, Department of Health and Human Services, Bethesda, Maryland; No We thank the EAGLE participants and the large number of collaborators (listed in http://dceg.cancer.gov.libproxy.lib.unc.edu/eagle) that made the EAGLE study possible, the CHTN that provided samples and data for the replication study, and Drs. Giuseppe Giaccone and Adi Gazdar for their insightful comments.
Grant Support: Intramural Research Program of NIH , NCI, Division of Cancer Epidemiology and Genetics, and a 2006 NCI Director's Innovation Award to M.T.L.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Cancer Research Volume 71, Issue 8 Supplement Apr-11 Abstract 3741: Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women Rachel E. Ellsworth1, Lori A. Field2, Brenda Deyarmin2, Brad Love3, Jeffrey Hooke4, and Craig Shriver4 1 Henry M. Jackson Foundation, Windber, PA
2 Windber Research Institute, Windber, PA
3 BioReka, Timonium, MD
4 Walter Reed Army Medical Center, Washington, DC.		 ©2011 American Association for Cancer Research 10.1158/1538-7445.AM2011-3741 Employee 4 Walter Reed Army Medical Center, Washington, DC. No N/A
Molecular Cancer Therapeutics Volume 12, Issue 11 Supplement Nov-13 Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Erin M. Coffee1, Anthony C. Faber1, Carlotta Costa1, Anahita Dastur1, Hiromichi Ebi1, Aaron N. Hata1, Alan T. Yeo1, Elena J1, Youngchul Song1, Ah Ting Tam1, Jessica L. Boisvert1, Randy J. Milano1, Jatin Roper2, David P. Kodack3, Rakesh K. Jain3, Ryan B. Corcoran1, Miguel N. Rivera1, Sridhar Ramaswamy1, Kenneth E. Hung2, Cyril H. Benes1, and Jeffrey A. Engelman1 1 Massachusetts General Hospital, Charlestown, MA
2 Tufts Medical Center, Boston, MA
3 Harvard Medical School, Boston, MA		 N/A 10.1158/1535-7163.TARG-13-C263 False Positive; Search Rerun No government agencies appear in author affiliations No N/A
Cancer Research Volume 72, Issue 8 Supplement Apr-12 Abstract 942: CYP3A4 epoxygenase mediates hypoxia-induced biosynthesis of epoxyeicosatrienoic acids (±)-11,12- and (±)-14,15-EET in breast cancer cells Zhijun Guo1, Ranjana Mitra2, Xiangghua Luo1, Jorge Capdevila3, JohnL Lipscomb1, and Potter A. David1 1 Univ. of Minnesota, Minneapolis, MN
2 Nevada Cancer Institute, Las Vegas, NV
3 Vanderbilt University, Nashville, TN		 N/A 10.1158/1538-7445.AM2012-942 False Positive No government agencies appear in author affiliations No N/A

Number of Federal Employee Authors: 32

Number of total works with works of govt disclaimers: 1

Number of National Lab Authors: 0

Number of works with works of govt disclaimers from national labs: 0

Number of Contractor (Non Natl Lab) Authors: 0

Number of False Positives that have had searches rerun: 15

Number of False Positives that have not had searches rerun: 2

Number of works with unclear authorship: 1

Number of works that could not be located: 0

Number of works that UNC does not provide access to: 0